Bachem Holding (Suzhou): difference between revisions
Diff·revision 13 → 14·10:44, 14 Feb 2025
Difference between revision 13 and revision 14 of Bachem Holding (Suzhou). 11 lines changed; the page grew by 860 bytes.
| Revision 13 — 02:16, 30 Jan 2025 BUD_Bertram (talk) add the lead time for catalogue lines, as reported 7,241 bytes +611 | Revision 14 — 10:44, 14 Feb 2025 CategoryBot (talk) bot: sort category members 8,101 bytes +860 | ||
|---|---|---|---|
| 52 | Submitted reports on BCH material to July 2026 span the incretin range and a set of repair peptides. Reported [[Area percent purity|area percent]] figures have been high and consistent with the accompanying certificates where both are available.{{r|reports}} | 52 | Submitted reports on BCH material to July 2026 span the incretin range and a set of repair peptides. Reported [[Area percent purity|area percent]] figures have been high and consistent with the accompanying certificates where both are available.{{r|reports}} |
| 53 | 53 | ||
| + | 54 | The set includes one report on a sequence for which no [[Reference standard|certified reference standard]] is commercially available. A purity figure obtained without a qualified standard is a statement about relative peak areas and cannot be converted into a potency; that limitation applies to the report and not to the material.{{r|usp1503,iso17025}} | |
| + | 55 | ||
| 54 | == References == | 56 | == References == |
| 55 | {{reflist}} | 57 | {{reflist}} |
| ⋮ | ⋮ | ||
| 58 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | 60 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> |
| 59 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 61 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 62 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| + | 63 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 60 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 64 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 61 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 65 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| + | 66 | ||
| + | 67 | == See also == | |
| + | 68 | * [[Certificate of analysis]] | |
| + | 69 | * [[Third-party testing]] | |
| + | 70 | * [[Area percent purity]] | |
| + | 71 | * [[Peptide content]] | |
| + | 72 | * [[Research use only]] | |
| 62 | 73 | ||
| 63 | {{DEFAULTSORT:Bachem Holding (Suzhou)}} | 74 | {{DEFAULTSORT:Bachem Holding (Suzhou)}} |